What did @kylieajohnston actually say?
Kylie stopped Ozempic due to Canada's supply shortage and framed it as an experiment. She reported losing an additional four pounds after stopping, stabilizing between 187 and 191 pounds. She also claimed that "food noise" largely did not return, at least for the first few weeks, and attributed her stable weight partly to habits built over ten months on the medication.
To be clear about what this is: a single person's anecdote over roughly four to five weeks. She did not claim to have clinical data. She was transparent about her financial barrier to continuing and honest that she still wants to lose more weight. That kind of self-awareness is worth noting.
Does the science back this up?
Partially, but the picture is more complicated than a month of stability suggests. Most clinical evidence points in the opposite direction from her experience.
The STEP 4 trial (Rubino et al., 2021, New England Journal of Medicine) is the most relevant data here. Participants who stopped semaglutide after 20 weeks of treatment regained roughly two-thirds of their lost weight within a year. The SURMOUNT-4 trial for tirzepatide (Aronne et al., 2024, JAMA) showed similar rebound patterns after discontinuation.
The mechanism matters. GLP-1 receptor agonists suppress appetite partly by acting on the hypothalamus and slowing gastric emptying. When the drug clears your system, those effects fade. The half-life of semaglutide is about one week, meaning it takes several weeks to fully clear. Kylie's four-week window may still partially overlap with residual drug activity, which could explain why food noise hadn't fully returned yet.
Habit formation is real, but its protective effect against weight regain post-GLP-1 is not well-studied. Some behavioral research (Tronieri et al., 2019, Obesity Reviews) suggests that structured habit reinforcement during pharmacotherapy improves long-term outcomes, but this hasn't been tested rigorously in GLP-1 discontinuation specifically.
What did they get wrong (or right)?
She got the framing mostly right, but the timeline is the problem. One month is not enough to draw conclusions about weight maintenance after GLP-1 discontinuation.
What she got right: she did not claim the medication was permanent or that her results were universal. She said "I'm okay with that," not "this works for everyone." She also correctly identified food noise as a real phenomenon that GLP-1s suppress, which is supported by neuroimaging and appetite research (ten Kulve et al., 2016, Diabetes Care).
What she underplayed: the gradual nature of rebound. Weight regain after stopping semaglutide typically accelerates between weeks six and twenty-four, not in the first four weeks. Her experience of losing four pounds immediately after stopping is unusual and could reflect water weight, normal fluctuation, or residual drug effect. Presenting this as evidence of success is premature.
She also does not mention that Ozempic is semaglutide at doses approved for type 2 diabetes, not obesity, which is a distinction that matters clinically even if it doesn't change her personal experience.
What should you actually know?
If you're watching this video and wondering whether you can stop GLP-1 therapy and keep your results, the honest answer is: most people cannot, at least not long-term.
The STEP 4 data is hard to ignore. Two-thirds of lost weight returning within a year is not a fringe result. It is the central finding of one of the largest GLP-1 discontinuation trials ever run. That does not mean Kylie's experience is fake. It means her experience at four weeks is not representative of what typically happens at twelve or twenty-four weeks.
There is also the Canada-specific shortage context. Health Canada confirmed ongoing semaglutide supply disruptions in 2023 and 2024. Many Canadian patients have been forced off therapy involuntarily, and the financial barriers she describes are real. The list price of Ozempic pens in Canada without coverage can exceed $300 to $500 per month depending on dose.
If you are considering stopping a GLP-1 medication, that is a conversation for a prescribing clinician, not a TikTok comment section. Stopping abruptly without a plan is different from a supervised taper or transition strategy.